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Abstract
Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer-related
deaths. Surgery is the only viable treatment, but irradical resection rates are still high.
Laparoscopic pancreatic surgery has some technical limitations for surgeons and tumor
identification may be challenging.  Image-guided techniques provide intraoperative
margin assessment and visualization methods, which may be advantageous in guiding
the surgeon to achieve curative resections and therefore improve the surgical outcomes.
In this chapter, current available laparoscopic surgical approaches and image-guided
techniques for pancreatic surgery are reviewed. Surgical outcomes of pancreaticoduo-
denectomy and distal pancreatectomy performed by laparoscopy, laparoendoscopic
single-site surgery (LESS), and robotic surgery are included and analyzed. Besides,
image-guided techniques such as intraoperative near-infrared fluorescence imaging
and surgical  navigation  are  presented  as  emerging  techniques.  Results  show that
minimally invasive procedures reported a reduction of blood loss, reduced length of
hospital stay, and positive resection margins, as well as an improvement in spleen-
preserving rates, when compared to open surgery. Studies reported that fluorescence-
guided pancreatic surgery might be beneficial in cases where the pancreatic anatomy is
difficult to identify. The first approach of a surgical navigation system for guidance
during pancreatic resection procedures is presented, combining preoperative images
(CT and MRI) with intraoperative laparoscopic ultrasound imaging.
Keywords: pancreatic cancer, laparoendoscopic single-site surgery, robotic surgery,
image-guided surgery, surgical navigation, near-infrared fluorescence
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1. Introduction
Cancer is the second leading cause of death worldwide after heart disease, with 14.9 million
cases and 8.2 million deaths in 2013 [1, 2] and the first leading cause of death among adults
aged 40–79 years [3, 4]. Worldwide, pancreatic ductal adenocarcinoma (PDA) is the fourth
leading cause of cancer-related deaths [2, 3]. The incidence of all types of pancreatic cancer
ranges from 1 to 10 cases per 100,000 people and is generally higher in developed countries
and among men [1, 2]. This has remained stable for the past 30 years relative to the incidence
of other common solid tumors [5]. Each year about 233,000 new cases of pancreatic cancer are
diagnosed worldwide [2, 3]. In the United States, the American Cancer Association expected
about 48,960 (24,840 men and 24,120 women) cases of incidence in pancreatic cancer in 2015,
with a mortality rate of 83% [6]. In Europe, the estimated number of new cases of pancreatic
cancer in 2012 was 79,331 and the estimated number of cases of deaths was 78,669 [7, 8], which
is almost the double than in the United States. The 5-year survival rate in the world for
pancreatic cancer is still very low, with only 6%. In addition, the overall 2-year survival rate
is less than 10%, which has hardly improved over the past two decades [3–5]. In fact, in
contrast to the stable or declining trends for most cancer types in the United States, a trend
analysis for 2001–2010 indicated that death rates are rising for pancreatic cancer [3, 4].
Figure 1. Anatomy of the pancreas. Source: "Blausen Gallery 2014". Wikiversity Journal of Medicine. DOI:
10.15347/wjm/2014.010. ISSN 20018762.
Pancreatic tumors are mainly classified as exocrine and endocrine tumors, also known as
pancreatic neuroendocrine tumors (NETs). Exocrine tumors are approximately 99% of all
primary pancreatic tumors [9] and are divided into ductal adenocarcinomas (80–90% of
exocrine tumors), cystic neoplasms, and solid pseudopapillary neoplasms [5, 6, 10]. Ductal
adenocarcinomas usually begin in the ducts of the pancreas and are located in the head of the
pancreas (60–70%) (Figure 1) [10]. Approximately 5–10% of PDA cases are believed to be due
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to hereditary conditions, such as hereditary pancreatitis, Gardner syndrome, familial colon
cancer, and others [11].
Pancreatic cases are usually diagnosed at an advanced stage but with few treatment options
available. This is attributed primarily to a lack of reliable methods for early diagnosis and rapid
metastasis of pancreatic cancer [12]. At the time of diagnosis, less than 20% of patients with
pancreatic cancer present with localized, potentially curable tumors [13, 14]. Approximately,
30% of patients receive a diagnosis of advanced loco-regional disease. In addition, 30% of
patients have local recurrence of tumors after treatment for an early disease [14].
Although there are several available treatments for pancreatic cancer such as ablative techni-
ques, radiation therapies, and chemotherapy, surgery is the only viable treatment. However,
only 10–20% of pancreatic tumors are candidates to be surgically resected at diagnosis [10,
15]. The required surgical intervention for pancreatic cancer treatment depends on the location
of tumors. Cancers arising in the head of the pancreas require a pancreaticoduodenectomy
(Whipple operation), while those in the tail require a distal pancreatectomy with or without
splenectomy [16]. Lesions located in the neck and body may require a distal pancreatectomy,
pancreaticoduodenectomy or, rarely, a total pancreatectomy. After surgery, patients with no
positive resection margins (R0) have the most favorable prognosis [17]. The median survival
length reported for resected (R0) pancreatic cancer ranges from 17–27 months and, after a R1
resection, the average survival length is 10.3 months [18]. However, irradical resection of
pancreatic cancers still occurs in 35–42% of patients [16, 19]. This survival time is longer in
patients with malignant disease localized to the pancreas and less than 3 cm in diameter than
in patients with tumors of greater size or with retroperitoneal invasion (6–15 months) [13].
Other factors, such as tumor size, lymph node status, tumor grade and blood vessel invasion,
are also correlated with prognosis [20].
The introduction of minimally invasive surgical techniques in the treatment of pancreatic
cancer has allowed almost any pancreatic tumor to be operated by laparoscopic or robotic
approaches with similar outcomes to the standard approach [21, 22]. Even new approaches
such as laparosendoscopic single-site surgery (LESS) are being applied recently in the field of
pancreatic surgery [23, 24]. However, there are some limitations that have hindered the wide
use of minimally invasive pancreatic surgery, mainly due to the challenges of these kinds of
interventions. The retroperitoneal location of the pancreas makes it difficult to reach during
surgery. In addition, this glandular organ presents a delicate structure close to major vascular
structures. There are also some technical limitations related to minimally invasive surgery
(MIS) such as the lack of visual and tactile information. Increasing the capability to visualize
tumor margins or to identify small metastatic nodules may significantly improve the surgical
procedure to prevent positive resection margins, and therefore, surgical outcomes [25]. Image-
guided techniques can provide intraoperative margin assessment and visualization methods,
which may be advantageous in guiding the surgeon to achieve curative resections. Some of
these emerging modalities are intraoperative near-infrared fluorescence imaging and surgical
navigation systems [26, 27]. However, despite the high rate of positive resections in pancreatic
surgery, there is limited medical literature regarding the use of navigation systems as a support
during pancreatic interventions. In this chapter, the current laparoscopic surgical techniques
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and image-guided methods for pancreatic surgery and their associate surgical outcomes will
be reviewed.
2. Laparoscopic techniques for pancreatic surgery
Pancreatic cancer is a complex disease, whose optimal treatment depends heavily on careful
accurate staging [28]. Surgical resection is still the only potentially curative therapy for
pancreatic cancer. However, pancreatic resection is technically challenging and a complex
surgical procedure. In this section, the current laparoscopic surgical techniques for pancreatic
surgery and their associated surgical outcomes will be reviewed. In order to reach more
representative information, only studies published after 2010 and with more than 50 patients
included, were taken into account. No limitation in the number of patients was set for the
studies using LESS.
2.1. Laparoscopic surgery
2.1.1. Laparoscopic pancreaticoduodenectomy
The first laparoscopic pancreaticoduodenectomy (LPD) was published by Gagner and Pomp
in 1994 [29]. They concluded that, although technically feasible, this approach did not confer
significant benefit over the conventional open approach in terms of postoperative outcomes
or reduced postoperative recovery period. One of the largest barriers of this complex procedure
is the reconstruction phase due to the three separate anastomoses to be performed (pancrea-
ticojejunostomy, hepaticojejunostomy, and gastrojejunostomy).
N Conv.
(%)
Time
(min)
EBL
(ml)
LHS
(days)
Morb.
(%)
Mort.
(%)
PF
(%)
LN
(%)
R0
(%)
[30] 53 17 541 195 8 77.3 5.7 13.2 44.2 94.9
[31] 384 10 5.2 4.7 80
[32] 983 5. 1
[33] 108 379.4 492.4 6
[34] 65 4.6 368 240 7 40 1.5 16.9 23.1 89
[35] 105 4.7 487.3 15 25 0.9 5.7 12.4 100
[36] 96 3.1 0 28.1
[37] 75 13.3 551 7 31 9.3
[38] 137 480.4 592 14.1
[39] 681 9 39.4 3.8
N: number of patients; Conv.: conversions; EBL: estimated blood loss; LHS: length of hospital stay; Morb.: morbidity
rate; Mort.: mortality rate; PF: pancreatic fistulas; LN: lymph nodes; R0: R0 resection rate.
Table 1. Reported outcomes in laparoscopic pancreaticoduodenectomy.
A summary of the outcomes reported for LPDs are presented in Table 1. The average operation
time was 486.7 min (range 368–551 min), 8.5% (range 3–17%) conversions, 342.3 ml (range 195–
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592 ml) blood loss, 8.9 days (range 6–15 days) hospital stay, 32% (range 25–40%) morbidity,
2.6% (range 0–5%) mortality, 14.7% (range 6–28%) pancreatic fistulas, 21.1% (range 6–28%)
harvested lymph nodes, and 89.7% (range 80–100%) R0 resection. The highest rate of conver-
sions reported was due to suspected portal vein involvement [30]. Regarding morbidity rates,
the highest rate was caused mainly by surgical site infection, postoperative pancreatic fistula,
and intraabdominal access [30]. Myocardial infarctions and positive margins were the main
mortality causes [30, 31]. Comparing these results with the conventional open approach [16],
LPD leads to an increase in operating time, rate of pancreatic fistulas, and R0 resections; a
decrease in estimated blood loss and harvested lymph nodes; and similar results in length of
hospital stay, morbidity, and mortality rates.
Most of the studies reported longer operation times using the laparoscopic approach compared
to the open approach [30, 35, 37]. Although some studies reported comparable outcomes
between open and LPD [30], in general, reduction of blood loss and hospital stay [33, 34] are
shown for LPD. In some studies, LPD was associated with equivalent overall hospital cost
compared with open pancreaticoduodenectomy [37, 39]. While operating time and supply
costs were higher for LPD, it was balanced by reduced cost due to the shorter postoperative
hospital stay. A steep learning curve is another aspect associated with LDP and some re-
searchers stated that this procedure should be performed in centers by surgeons with sub-
stantial knowledge, experience, and skills [34, 36].
2.1.2. Laparoscopic distal pancreatectomy
Laparoscopic distal pancreatectomy (LDP) was first reported in 1996 by Gagner and Cuschieri
[40, 41]. During this intervention, the tail of the pancreas or the tail and a portion of the body
of the pancreas are removed. In some cases, the spleen is also removed. This operation is used
more often to treat pancreatic NETs found in the tail and body of the pancreas. The determi-
nation of resectability is often based on the extent of involvement of the celiac axis [42].
A summary of the outcomes for LDPs are shown in Table 2. In brief, the average operation
time was 215.2 min, 12% conversion rate, 241.7 ml estimated blood loss, 7.6 days length of
hospital stay, 32.5% morbidity rate, 0.3% mortality rate, 21.2% pancreatic fistulas, 10.2%
harvested lymph nodes, 89.5% R0 resection, and 46.3% spleen-preserving rate. Comparing
these results with the outcomes from conventional open surgery [43, 44], there is a decrease in
operation time, estimated blood loss, length of hospital stay, and mortality rate; similar
morbidity rates; and an increased rate of pancreatic fistulas and spleen preservation.
Satisfactory oncological outcomes have been reported for LDP in patients with PDA and left-
side pancreatic neoplasms [58, 61]. Although some studies reported similar outcomes as open
distal pancreatectomy [21], most of the studies reported a clear reduction of blood loss [50, 53,
62, 63, 65] and hospital stay [45, 48, 50, 53, 31, 59, 61–65]. An increase in quality of life is reported
when compared to the conventional approach [46]. Similar costs for the laparoscopic and open
approaches are reported [63]. The increased OR cost associated with LDP is often offset by the
shorter hospitalization and lower overall cost of postoperative care [57].
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Regarding the spleen-preserving rate, results stated that it is worth to attempt laparoscopic
spleen-preserving DP in patients with a presumed benign to borderline tumor of the body-tail
of the pancreas [54]. The most positive results were reported for the splenic vessels preservation
technique regarding the conservation of the spleen [51, 66].
N Conv.
(%)
Time
(min)
EBL
(ml)
LHS
(days)
Morb.
(%)
Mort.
(%)
PF
(%)
LN
(%)
R0
(%)
SP
(%)
[21] 64 32.8 213 275 8 16 11 8 62 79.6
[45] 535 22.8 7 0 15 86
[46] 100 23 239 464 7.7 66 0 53 73.3
[47] 94 0 11
[48] 71 9.1 250 150 5 28.2 0 11 97.2 15.5
[49] 67 14.9 203 100 6 21 1.5 19 6
[50] 107 30 193 150 5 27 0 15 97 21
[51]* † 55 9 214.7 342.8 8.2 27.3 0 16 93.4
[51]* † 85 13 199.2 288.9 10.5 38.8 0 26 3 84.7
[52] 132 6.1 156.5 197.4 6 43.2 0.8 21 8 96.2 9.8
[53] 131 31.3 193 262 5 32 0 8 11 100 22.1
[54] 100 2 207 8.7 49 0 27 98 41
[55] 143 5.6 236 334 17
[56] 902 6.4 316 243 18.9 23.6 66 11 32
[57] 70 7.1 145 113 5.8 49 0 36 5
[58] 196 2.5 220 250 8 31.9 0 24 10 83.8
[59] 144 39.5 6.8 0 17 87
[60] 70 7.1 239 9 25.7 0 19 3 75.7
[61] 359 195 8 12 0 28 20 91.6 49.6
[62] 82 7 188 70 4 32.9 0 13 97 12
[63] 100 4 214 171 6.1 34 3 17 15 100 25
[64] 73 15 352 5 40 0 22 97
[65] 45 0 158.7 122.6 7.9 26.7 16 53.3
[66]† 70 0 220 352 10.4 32.9 0 17 100
[67]* † 246 0 193.4 378 8.2 32.5 0 20 54.8
[67]* † 203 0 204.4 328 7.7 25 0 4
N: number of patients; Conv.: conversions; EBL: estimated blood loss; LHS: length of hospital stay; Morb.: morbidity
rate; Mort.: mortality rate; PF: pancreatic fistulas; LN: lymph nodes; R0: R0 resection rate; SP: spleen preserving.
*Two groups.
†Spleen-preserving DP.
Table 2. Reported outcomes in laparoscopic distal pancreatectomy.
With growing surgical experience and refinement in the surgical technique, the indications for
LDP have substantially broadened [52]. In this sense, the learning curve appeared to have been
completed after 17 procedures [68], but strict selection criteria, high-volume hospital, and
experienced team in open pancreatic surgery may play an important role in shortening this
learning curve [69].
Laparoscopic Surgery70
2.2. Laparoendoscopic single-site surgery
Recent interest in improving cosmetic outcomes has led to laparoendoscopic single-site
surgery (LESS) being performed in a variety of procedures. In this sense, LESS is now con-
solidated as a real alternative to conventional laparoscopic surgery, with numerous studies
sustaining its feasibility and therapeutic safety. However, single-site pancreatectomy has been
explored and described only in recent years, and therefore, literature is limited to DP proce-
dures and mostly to single case reports or small case series, as it is considered to be a chal-
lenging procedure. Only one study has been found for a PD through the single-site approach
[70]. In this case, a surgical resection for a malignant melanoma metastatic to the pancreas was
performed. The resection was carried out preserving the pylorus. No detailed information
about the intervention and surgical outcomes were reported.
N Conv.
(%)
Time
(min)
EBL
(ml)
LHS
(days)
Morb.
(%)
Mort.
(%)
PF
(%)
LN
(%)
R0
(%)
SP
(%)
[23] 20 176 2 4 20 20 0 100 90
[24] 14 7.1 166.4 157.1 7.6 0 7.1 0 50
[71] 1 0 330 100 7 1 100 0 100 0
[72] 1 0 170 5 0 100 0
[73]† 1 0 233 <100 3 0 100 100
[74] 12 20 279.8 185 12.2 3 41.6 25 100 33.3
[75] 8 0 145 225 6 2 50 25 100 62.5
[76]* 2 0 232.5 100 7, 5 0 100
[77] 1 0 5 0 0 100 0
N: number of patients; Conv.: conversions; EBL: estimated blood loss; LHS: length of hospital stay; Morb.: morbidity
rate; Mort.: mortality rate; PF: pancreatic fistulas; LN: lymph nodes; R0: R0 resection rate; SP: spleen preserving.
*Two groups.
†Spleen-preserving DP.
Table 3. Reported outcomes in single-site distal pancreatectomy.
The average operation time reported for LESS distal pancreatectomy (Table 3) was 218 min
(range 145–330 min), 3% (range 0–20%) conversion rate, 144 ml (range 100–225 ml) estimated
blood loss, 6 days (range 2–12 days) length of hospital stay, 15% (range 0–50%) morbidity, 0%
mortality, 100% R0 resection, and 42% (range 0–100) spleen-preserving rate. Comparing the
results with the conventional laparoscopic approach, there is a decreased rate of conversions,
estimated blood loss, length of hospital stay, and morbidity; a similar mortality rate; increased
average of pancreatic fistulas and R0 resections; and lower spleen-preserving rate.
Barbaros et al. [71] reported the first transumbilical laparoscopic single-site DP in a patient
with metastatic lesions on the pancreas. The patient developed a pancreatic fistula. Haugvik
et al. [75] compared the results of 8 single-incision DPs with 16 conventional LDPs. They
reported no significant differences in operative time, intraoperative bleeding, resection status,
and hospital stay between the two groups. Four surgical complications were reported for LESS
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and five for the conventional approach, including two patients for each group who developed
a pancreatic fistula. There was no conversion to conventional laparoscopic or open surgery in
any procedure. No differences between operative and postoperative results were also obtained
by Yao et al. [24], who compared the surgical outcomes of 14 transumbilical laparoscopic
single-site DPs with seven conventional multiport interventions. One conversion to open
surgery and one case of leakage were reported for the LESS interventions. Machado et al. [23]
reported 4 cases of pancreatic fistula in a study of 20 DPs. Some cases reported no surgical
complications during the intervention [72, 76]. In a case study without using any commercial
surgical port for LESS [77], the patient developed fever and leukocytosis after surgery. Bracale
et al. [72] presented the first LESS DP for an adenocarcinoma. They reported no postoperative
complications after 4 months follow-up.
Spleen preservation is an important issue in patients undergoing DP. However, only a few
studies have reported spleen preservation through LESS. Chang et al. [73] reported a case of
ransumbilical LESS spleen-preserving DP for a cystic tumor in the body of the pancreas. No
surgical complications were reported. In another study, Han et al. [74] compared the results
from 12 LESS DPs to 28 cases using a conventional laparoscopic approach. The mean surgery
time and hospital stay in the LESS group were significantly longer. The spleen preservation
was possible in 60.7% of the patients who underwent the conventional approach and 33.3%
for the LESS. No significant differences in intraoperative blood loss, tumor size, conversion
rate, and postoperative complications between the two groups were found.
In general, authors stated that single-site laparoscopic PD is a feasible and safe technique [23,
72, 74], which can be successfully performed in selected cases and qualified centers [71, 73].
However, they also stated that it is a very demanding procedure with a steep learning curve
[74].
2.3. Robotic surgery
Robotic platforms, as the da Vinci® Surgical System (Intuitive Surgical, Sunnyvale, CA, USA),
try to overcome many of the key shortcomings of traditional laparoscopy that include
monocular vision, limited degrees of freedom, and the effects of pivot and fulcrum, which
make complex tasks difficult to master. However, there are also some drawbacks regarding
the use of these systems such as the lack of tactile feedback and their cost, including mainte-
nance. Since its first reported application in 2003 [78], the application of robotic technology in
pancreatic interventions has been increasing. The main benefit of robotic-assisted PD in
comparison with LPD may be the ease of intracorporeal reconstruction after a long resection
[78].
In the scientific literature, most of the studies regarding the robotic-assisted PD and DP are
retrospective reviews and case reports (Table 4 and 5). The average operation time reported
for robot-assisted PD (Table 4) was 489.1 min (range 410–568 min), 10% (range 0–22%)
conversion rate, 324 ml (range 250–400 ml) estimated blood loss, 13.4 days (range 9–22 days)
hospital stay, 48.6% (range 21–67%) morbidity rate, 3.8% (range 1–7%) mortality rate, 17.4%
(range 7–30) pancreatic fistulas, 29% (range 11–70%) harvested lymph nodes, and 91% (range
87–95%) R0 resection. Comparing the results with conventional laparoscopic approach,
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operative time, length of hospital stay, and negative resections margins are similar; the rate of
conversions, morbidity, mortality, and pancreatic fistulas are increased. Positive results have
been obtained for robotic-assisted PD in patients with aberrant or anomalous hepatic arterial
anatomy [22]. In a prospective analysis with 150 patients, Polanco et al. [79] concluded that
larger body mass index, higher EBL, smaller tumor size and smaller duct diameter are the main
predictors of postoperative PF in robot-assisted PD. It appears that the learning curve for robot-
assisted PD is attained within 80 cases [80].
N Conv.
(%)
Time
(min)
EBL
(ml)
LHS
(days)
Morb.
(%)
Mort.
(%)
PF
(%)
LN
(%)
R0
(%)
[22]* 112 0 500 250 9.5 63.3 6.7 7 20 92.6
[79] 150 7.3 515 300 17
[80] 200 6.5 483 250 9 67.5 3.3 17 11 92
[84] 60 410 400 20 35 1.7 13 23 94.7
[85] 50 22 421 394 22 30 70 90
[86] 50 16 568 350 10 56 2 20 36 89
[87] 132 8.3 527 >400 10 21 5.3 17 14 87.7
N: number of patients; Conv.: conversions; EBL: estimated blood loss; LHS: length of hospital stay; Morb.: morbidity
rate; Mort.: mortality rate; PF: pancreatic fistulas; LN: lymph nodes; R0: R0 resection rate; SP: spleen preserving.
*Two groups.
Table 4. Reported outcomes in robotic-assisted pancreaticoduodenectomy.
N Conv.
(%)
Time
(min)
EBL
(ml)
LHS
(days)
Morb.
(%)
Mort.
(%)
PF
(%)
LN
(%)
R0
(%)
SP
(%)
[45] 535 23 7 3 86
[82] 100 2 246 150 72 0 42 13 95.7
[83] 55 0 278.2 12.6 61.8 0 53 58 100 61.8
[87] 83 2.4 256 >200 6 13 0 43 17 97
[88]† 69 0 150 100 11.6 40.6 0 25 22 100 65.2
N: number of patients; Conv.: conversions; EBL: estimated blood loss; LHS: length of hospital stay; Morb.: morbidity
rate; Mort.: mortality rate; PF: pancreatic fistulas; LN: lymph nodes; R0: R0 resection rate; SP: spleen preserving.
†Spleen-preserving DP.
Table 5. Reported outcomes in robotic-assisted distal pancreatectomy.
Regarding robot-assisted DP, the average operation time was 232.6 min (range 150–278 min),
5.5% (range 0–23%) conversion rate, 125 ml (range 100–150 ml) estimated blood loss, 9.3 days
(range 6–13 days) hospital stay, 46.9% (range 13–72%) morbidity rate, 0% mortality rate, 40.7%
(range 24–53%) pancreatic fistula, 22.6% (range 3–58%) harvested lymph nodes, 95.7% (range
86–100%) R0 resection, and 63.5% (range 62–65%) spleen-preserving rate. Comparing these
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results with the conventional laparoscopic approach, there is a decreased conversion rate and
EBL; and increased operation time, length of hospital stay, morbidity, rate of pancreatic fistulas,
R0 resections, and spleen-preserving rate. Morbid obesity and technical difficulty seem to be
the two most common reasons for conversion from robotic-assisted hepatobiliary and pan-
creatic surgery [81]. It appears that the learning curve for robot-assisted DP is approximately
10–40 cases [82, 83].
3. Image-guided techniques for pancreatic surgery
In order to cope with some of the limitations in MIS and guide the surgeon during the surgical
procedure, image-guided techniques have been developed. The lack of tactile feedback and
3D sensation in video-assisted surgery accelerated the need for these techniques. In addition,
for the human eye, several pathologies, such as the presence of nonsuperficial tumors, are not
easily distinguishable from surrounding normal tissue. This makes, in some occasions,
decision-making during surgery a very difficult process. During image-guided surgery,
diagnostic imaging is used in conjunction with images from the operative field to improve the
localization and targeting of pathologies, as well as to monitor and control treatments. The
combination of tracking technologies for recording the position of the patient and the surgical
instruments with preoperative and intraoperative images provides a comprehensive assis-
tance tool for guiding any MIS intervention [27, 89–91]. Image-guided technology allows for
more precise and accurate procedures, allowing surgeons to decide the best approach to
address a specific disease before the intervention [92].
Radical surgical resection of tumor tissue is currently the best chance for cure. However, this
option is only suitable for a minority of patients, and surgical procedures are complex with
high rates of local recurrence. The presence of microscopic residual tumor tissue at the
resection margins is one of the main prognostic factors, and therefore optimizing the surgical
procedure to prevent positive resection margins is of the utmost importance. Accordingly,
intraoperative margin assessment and visualization techniques, as well as image-guided
techniques may be advantageous in guiding the surgeon to achieve curative resections.
3.1. Laparoscopic ultrasound (LUS)
Advances in technology over the last 30 years have seen the application of laparoscopic
ultrasound (LUS) expand beyond its initial limited diagnostic role to assisting in tumor staging,
guiding intervention, locating lesions intraoperatively, assessing anatomic relationships, and
in directed therapy [93–95]. The main application of LUS during pancreatic and liver surgery
is providing real-time imaging guidance for resectability assessment and detection of vessel
involvement, aiming to decrease the number of irradical resections [95]. The reported overall
sensitivity, specificity, and accuracy of combined diagnostic laparoscopy and LUS in predicting
resectability has been reported to be 100, 91, and 96%, respectively [96]. LUS should be
considered for confirmation of staging of disease when there is a strong suspicion of unre-
sectability and tumor borders are not clearly defined by CT scan [96].
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LUS plays an integral part in the management of cystic lesions of the pancreas, particularly
the characterization of suspected intraductal papillary mucinous neoplasms (IPMNs) [95, 97,
98]. IPMNs appear as well-defined hypoechoic masses with associated posterior enhancement.
The malignant potential of IPMNs is directly related to its relationship with the main pancreatic
duct and adjacent blood vessels (Figure 1). LUS allows defining the cysts borders (Figure 2)
and evaluating the relationship of the lesion with the main duct and any major vessels [95, 98,
99].
Figure 2. LUS image of a pancreatic cystic tumor. The lesion appears as a hypoechoic mass (yellow arrow).
In the case of pancreatic adenocarcinomas, they appear as a homogeneous hypoechoic mass
with poorly defined margins. Large tumors can display a mixed echogenicity. A sensitivity of
90% for assessing positive lymph nodes and 100% for venous invasion have been reported for
laparoscopy combined with LUS examination [100]. Regarding NETs, LUS facilitates intrao-
perative decision-making and demonstrates anatomic details, such as the tumor location and
its relation to the adjacent vascular structures and main pancreatic duct [95, 97]. In ultrasound
images, NETs typically appear as well-defined, homogeneous, and hypoechoic masses [93].
Findings from LUS inspection help to decide whether to perform either tumor enucleation or
resection during laparoscopic intervention [93].
3.2. Fluorescence
Near-infrared (NIR) light (700–900 nm) is a novel imaging technique that can penetrate through
several millimeters even centimeters of tissue, revealing targets below the tissue surface [101].
This imaging modality does not use ionizing radiation or direct tissue contact, making it a
remarkably safe technique. NIR fluorescent contrast agents can be visualized with acquisition
times in the millisecond range, enabling real-time guidance during surgery. Furthermore, as
NIR light is invisible to the human eye, it does not alter the look of the surgical field, thus
minimizing the learning curve [102]. The main aim of this imaging modality is to fill the gap
between preoperative imaging and intraoperative reality.
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Fluorescence-guided systems provide an additional tool for diagnosis of pancreatic cancer,
real-time image guidance during tumor resection, and inspection to confirm complete
resection [103]. This intraoperative modality can assist surgeons to visualize tumors, sentinel
lymph nodes, and vital structures in real time [102]. This technology could represent the next
step to improving treatment of pancreatic cancer in laparoscopic resections. However, most of
the published studies for pancreatic surgery are limited to animal models.
Two main components are needed for fluorescence-guided surgery, fluorescent contrast agents
and a NIR camera system. Several intraoperative NIR fluorescence camera systems have been
developed for both open and laparoscopic surgery, some of which are commercially available
and Food and Drug Administration (FDA) approved [104]. Fluorescent contrast agents contain
a fluorescent component (fluorophore), which emits NIR fluorescent light after being excited
with a NIR light source. Visualization of the tissue is based on the signal of the contrast agent
in the region of interest relative to the background signal, known as signal-to-background ratio.
Indocyanine green (ICG) and methylene blue (MB) are the only NIR fluorophores that are
registered with the FDA and the European Medicines Agency for clinical use. ICG emits
fluorescent light at ≈800 nm and it is cleared rapidly by the liver and almost exclusively excreted
into the bile, permitting imaging of bile ducts. MB has been applied clinically for many years
as a visible contrast agent, and when diluted to levels that are almost undetectable to the human
eye, MB becomes a fluorophore emitting at ≈700 nm. MB is cleared equally by both liver and
kidney, permitting imaging of both bile ducts and ureters. ICG has been shown to accumulate
around hepatic metastasis of pancreatic and colorectal cancers [105]. Methylene blue tends to
accumulate in NETs after high-dose intra-arterial injection [103, 106]. The chemical structures
of both ICG and MB do not allow these agents to be conjugated to tissue-specific, therefore,
they are nonspecific NIR contrast agents [102, 107].
Applications of this technique during hepatopancreatobiliary surgery include tumor imaging
in liver and pancreas, and real-time imaging of the biliary tree. Pessaux et al. [26] presented a
robotic pancreaticoduodenectomy assisted by fluorescence imaging, providing enhanced
visualization of the common bile and cystic ducts during the intervention (Figure 1). Subar et
al. [108] reported a case of a LPD to treat an ampullary lesion in the duodenum. Before the
pancreaticojejunostomy, the viability of the margin of the remnant pancreas was assessed with
NIR imaging. The NIR technique improved the detection of ischemic tissue of the pancreatic
margin after resection. This may lead to an increase in blood supply to the pancreatic anasto-
mosis, and therefore potentially help to decrease the incidence of pancreatic fistulas.
In a study with different pancreatic tumors on three experimental porcine models, we analyzed
the usefulness of NIR imaging during laparoscopic pancreaticoduodenectomy and single-site
distal pancreatectomy procedures. In two animals, a tumor model was created in the head of
the pancreas. In the third animal, the tumor model was developed in the tail of the pancreas.
NIR imaging was used as guidance during LPD and LESS distal pancreatectomy. The patency
of the hepaticojejunostomy was assessed by means of ICG excretion and fluoroscopic imaging.
During surgery, identification of the biliary anatomy and vascular anatomy of the pancreas
was possible in all procedures using NIR imaging (Figure 3). Biliary excretion of ICG was not
clearly visualized during the patency test, but fluoroscopic imaging was positive in one case.
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Figure 3. NIR image of biliary and pancreatic anatomy: Cystic artery (a, yellow arrow), cystic duct (b, yellow arrow),
and pancreaticoduodenal artery (c, yellow arrow).
To obtain the full advantage of NIR fluorescence imaging for pancreatic cancer visualization,
such as tumor imaging, tumor specific NIR conjugated agents need to be designed and tested.
The tumor-targeting capability of the fluorophore-conjugated anticarcinoembryonic antigen
antibody has been demonstrated in orthotopic models for intraoperative tumor visualization
of both primary and metastatic deposits of pancreatic cancer [25, 109]. Metildi et al. [109]
concluded that mice treated with fluorescence-guided laparoscopic surgery permitted
adequate labeling and distinction of tumor margins before tumor resection, decreasing local
recurrence, and increasing survival compared to mice treated with standard bright-light
laparoscopic surgery.
3.3. Surgical navigation
Surgical navigation systems (SNS) combine preoperative and intraoperative image informa-
tion with position and orientation tracking of surgical instruments during the surgical
intervention as a surgical decision-making tool helping to improve the safety, accuracy, and
efficiency of surgeries [27, 91, 92]. In MIS, due to surgeon having less visual and tactile
perception compared to open surgery, image assistance becomes extensively helpful for 3D
understanding of the surgical scenario and localization of lesion and essential anatomic
structures.
The basic setup of a SNS consists of a preoperative image data (typically MR and CT), a tracking
system (mainly electromagnetic or optical), a computer platform with screen, and the respec-
tive navigation software [89]. The combination of image-guided surgery with navigation
technology consists of several steps, which are critical to ensure safety and accuracy of a
procedure [27]: (1) acquisition of preoperative images and visualization for optimal diagnosis
and planning, (2) accurate registration of preoperative data to the patient coordinate space and
visualization in the OR, (3) intraoperative image acquisition and visualization/fusion with the
preoperative images to update for anatomical shifts, and (4) postoperative imaging and
visualization for evaluation of the surgical treatment.
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Despite the use of navigation systems, abdominal surgery is still a challenging task. Commer-
cial SNS are available for resection and ablation procedures of the liver (example: CAScination
AG, Switzerland). However, to the best of our knowledge, no commercial systems are available
or studies in the scientific literature have been published regarding the use of SNS for assistance
during pancreatic cancer surgery.
We were recently able to demonstrate the usefulness of the CustusX navigation system for
image guidance during a patient case, a distal pancreatectomy for the resection of a cystic
tumor in the body of the pancreas (unpublished case). CustusX is an open-source navigation
research platform for image-guided interventions [91]. This platform has been successfully
used for many clinical applications such as neurosurgery, spine procedures, bronchoscopy,
endovascular therapy, and laparoscopic procedures like adrenalectomy and lately for liver and
pancreas surgery [91, 110–112].
Figure 4. Snapshot of the CustusX platform during a distal pancreatectomy. The tumor is shown in green and the pan-
creas in yellow. The US imaging is superimposed on the 3D model from a preoperative MRI scan.
Prior to surgery, MR and CT images were acquired and imported into the navigation system
software for reconstruction into 3D. The anatomical structures of interest, including the
pancreas, tumor, and vessels were segmented semiautomatically [112]. The navigation system
was integrated with a LUS probe running on an ultrasound scanner (Ultrasonix, Canada) with
digital research interface to the navigation system. The probe was tracked by an electromag-
netic sensor integrated in the tip. A probe calibration was carried out in a laboratory using a
robotic arm and a well-defined geometric structure in a water tank [113]. An intraoperative
registration procedure was carried out to combine the intraoperative LUS with the corre-
sponding preoperative MR and CT images, displaying them simultaneously (Figure 4). This
enabled the location of the lesion based on multimodal display, providing a useful tool for the
surgeons to identify the anatomical structures of interest, meet their relation to other adjacent
structures, and define safely and accurately the resection margin during the course of the distal
pancreatectomy.
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3.4. Augmented reality
Another available technology for intraoperative surgical guidance is augmented reality (AR).
In surgery, AR is the fusion of artificial computer-generated images (3D virtual model)
generally obtained from preoperative medical imaging and real-time patient images with the
aim to visualize unapparent anatomical details. This results in the visualization of internal
structures through overlying tissues, providing a virtual transparent vision of surgical
anatomy. Potential advantages of the use of this imaging technology in surgery include the
delineation of dissection planes or resection margins and the avoidance of injury to invisible
structures.
The registration process is one of the main challenges of AR, in which the virtual model and
intraoperative images should be merged in real time. In this sense, intraoperative accuracy is
highly affected by mobile or deformable structures due to the heartbeat, ventilation, or
laparoscopic insufflation.
A method to overlay anatomical information from preoperative CT studies onto the patient’s
body surface during gastrointestinal, hepatobiliary, and pancreatic surgery was presented by
Sugimoto et al. [114]. For enabling the simultaneous display of the gastrointestinal tract and
pancreatobiliary duct with associated blood vessels, a carbon dioxide-enhanced virtual
multiple detector CT cholangiopancreatography was performed. Manual registration based
on physiological markers was used. However, this method does not deal with possible
alteration of the patient anatomy during the course of the surgery. A robotic pancreaticoduo-
denectomy assisted by AR was presented by Pessaux et al. [26]. In this study, a 3D virtual model
of the patient from a preoperative CT scan was manually merged with the stereoscopic images
from the da Vinci® robotic system.
4. Conclusions
Pancreatic cancer has a high mortality rate and, at the time of diagnosis, the number of patients
with potentially resectable tumors is considerably low. Surgery is still the only viable option
for treatment of pancreatic cancer. However, surgical procedures for pancreatic resection are
complex and require high surgical expertise. Pancreatic tumors can be treated through
laparoscopic surgery with similar outcomes to the conventional approach. In general, studies
reported that minimally invasive pancreatic surgery is feasible, safe, and with a steep learning
curve. Laparoscopic procedures reported a reduction of blood loss, length of hospital stay, and
positive resection margins, as well as an improvement in spleen-preserving rates when
compared to open surgery. Laparoendoscopic single-site surgery reduces the blood loss and
morbidity, compared with the conventional laparoscopic approach. In robot-assisted pancre-
atic surgery, reported surgical outcomes are similar to laparoscopic surgery, with an apparent
increase in the splenic preservation rate and negative resection margins.
Laparoscopic pancreatic surgery has some technical limitations for the surgeon such as the
reduced tactile and visual information. Besides, intraoperative tumor identification may be a
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challenging task in some cases due to the anatomical location of the pancreas, nearby major
vascular structures, and frequently inflamed surrounding pancreatic tissue. These limitations
may significantly impact the surgical procedure to prevent positive resection margins. Image-
guided techniques provide intraoperative margin assessment and visualization methods,
which may be advantageous in guiding the surgeon to achieve curative resections, resulting
in improved surgical outcomes. Reported cases of fluorescence-guided pancreatic surgery
showed that this imaging technique could be beneficial in surgeries where the pancreatic
anatomy is difficult to identify. Navigation systems combine preoperative and intraoperative
imaging, providing location of the anatomical structures of interest with respect to surgical
instruments as well as the extent of the tumor to be addressed, which allows for a safe and
precise definition of resection margins. Thus, surgeons will have a comprehensive system to
support and guide pancreatic surgeries, with the ultimate goal of improving surgical outcomes
and increase the rate of negative resections and the subsequent positive effect on the life
expectancy of the patient.
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